Abramson Cancer Center Support Grant

艾布拉姆森癌症中心支持补助金

• 批准号: 9131243
• 负责人: CHI V. DANG
• 金额: $ 12.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-15 至 2015-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9131243
• 关键词: Area; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Clinical; Collaborations; Community Outreach; Comprehensive Cancer Center; Cutaneous Melanoma; Detection; Development; Direct Costs; Education; Faculty; Fostering; Funding; Future; Growth; Hematologic Neoplasms; Image; Immunobiology; Interdisciplinary Study; Laboratories; Leadership; Malignant Neoplasms; Medicine; Methods; Mission; National Cancer Institute; Patient Care; Patients; Pediatric Oncology; Peer Review; Pennsylvania; Pilot Projects; Process; Radiobiology; Research; Research Activity; Research Training; Resource Allocation; Resource Sharing; Schools; Strategic Planning; Therapeutic; Translating; Translational Research; Translations; Tumor Biology; United States National Institutes of Health; Universities; anticancer research; cancer prevention; clinical practice; environmental carcinogenesis; innovation; malignant breast neoplasm; member; population based; programs; proton therapy; tobacco carcinogenesis; tumor; virology

DESCRIPTION (provided by applicant): The Abramson Cancer Center (ACC) of the University of Pennsylvania was founded in 1973 and was one of the first Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Since its inception, the ACC has been continuously funded through the NCI CCSG. The ACC is a matrix center that facilitates transdisciplinary cancer research, education, and patient care. Its 318 members are drawn from 37 Departments and 8 Schools of the University and have $168,806,933 in research and training funding (annual direct costs), a 40% increase since 2004. Of these funds, $156,713,965 is peer-reviewed and $51,462,763 is NCI funded, this funding includes 16 NIH P01s, 5 P50s, 3 P30s, and 1 P20. Commensurate with the growth in funding, the ACC has more than doubled its assigned space since 2004 with the opening of the Perelman Center for Advanced Medicine, the Roberts Proton Therapy Facility, and the Fisher and Colket Translational Research Buildings. Through the development of integrated programs of laboratory, clinical, and population-based research, the ACC seeks to foster pioneering scientific discoveries that can be translated into new methods for cancer prevention, detection, and treatment. Currently, there are 11 multidisciplinary research programs in the ACC: Immunobiology, Tumor Biology, Tumor Virology, Cancer Therapeutics, Pediatric Oncology, Radiobiology and Imaging, Melanoma and Cutaneous Malignancies, Hematologic Malignancies, Breast Cancer, Tobacco and Environmental Carcinogenesis, and Cancer Control. The Cancer Center supports 13 Shared Resources, of which 2 are new and 2 have been restructured. The continuous development of strong Research Programs and leading-edge Shared Resources, the recruitment of outstanding faculty, and the acquisition of additional research space allow the ACC to support the research activities of its members. An ongoing strategic planning/implementation process allows the ACC to identify emerging cancer research areas for future development, while guiding current activities and resource allocations. The ACC supports a wide range of seminars and retreats and promotes interdisciplinary use of research space to facilitate interaction and collaboration among its members. Developmental funds remain critical for the support of faculty recruitment and the funding of innovative pilot projects with the potential for peer-reviewed funding and translation. The ACC has an engaged leadership focused on supporting the transdisciplinary cancer research of its productive membership.

描述（由申请人提供）：宾夕法尼亚大学的艾布拉姆森癌症中心（ACC）成立于1973年，是国家癌症研究所（NCI）指定的第一个综合癌症中心之一。自成立以来，ACC已通过NCI CCSG不断资助。 ACC是一个矩阵中心，可促进跨学科的癌症研究，教育和患者护理。它的318名成员来自37个系和8所大学，并拥有168,806,933美元的研究和培训资金（年度直接费用），自2004年以来增加了40％。在这些资金中，同行进行了156,713,965美元，同行进行了评估，并进行了51,462,763 $ 51,462,763 IS NCI Funds，其中包括16 NIH P01，P011 16 NIH，和16 nih p0，及P20。自2004年以来，随着Perelman高级医学中心，Roberts Proton Therapy设施以及Fisher和Colket转化研究建筑的开业，ACC与资金的增长相称，其分配的空间增加了一倍以上。通过制定实验室，临床和基于人群的研究的综合计划，ACC试图促进开拓性的科学发现，这些发现可以转化为预防癌症，检测和治疗的新方法。目前，ACC中有11种多学科研究计划：免疫生物学，肿瘤生物学，肿瘤病毒学，癌症治疗学，儿科肿瘤学，放射生物学和成像，黑色素瘤和皮肤恶性肿瘤，血液学恶性肿瘤，乳腺癌，烟草，烟草以及环境的营造量和癌症对照。癌症中心支持13个共享资源，其中2个是新的，其中2个已进行了重组。强大的研究计划和领先的共享资源，杰出教师的招募以及获得额外的研究空间的持续发展，使ACC可以支持其成员的研究活动。持续的战略规划/实施过程使ACC可以在指导当前的活动和资源分配的同时确定新兴的癌症研究领域。 ACC支持广泛的研讨会和务虚会，并促进了研究空间的跨学科使用，以促进其成员之间的互动和协作。发展资金对于支持教师招聘以及创新的试点项目的资金至关重要，并有可能进行同行评审的资金和翻译。 ACC的领导层致力于支持其生产成员的跨学科癌症研究。